^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    lutetium zadavotide guraxetan (PNT2002)

    i
    Other names: PNT2002, 177Lu-PSMA radiotherapeutic, 177Lu-PSMA-I&T, 177Lu-PNT2002, PNT-2002, PNT 2002
    Company:
    Eli Lilly, Lantheus
    Drug class:
    Ionizing radiation emitter, PSMA inhibitor
    Related drugs:
    1m
    PSMA Therapy and Immunotherapy in Kidney Cancer (clinicaltrials.gov)
    P1/2, N=37, Not yet recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Jul 2031 --> Jan 2032 | Initiation date: Nov 2024 --> May 2025 | Trial primary completion date: Jul 2030 --> Jan 2031
    Trial completion date • Trial initiation date • Trial primary completion date • Metastases
    |
    Keytruda (pembrolizumab) • lutetium zadavotide guraxetan (PNT2002)
    3ms
    177Lu-PSMA (177Lu-PNT2002) in PSMA-Positive Adenoid Cystic Carcinoma (clinicaltrials.gov)
    P2, N=10, Not yet recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Initiation date: Sep 2024 --> Dec 2024
    Trial initiation date
    |
    lutetium zadavotide guraxetan (PNT2002)
    3ms
    177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study (clinicaltrials.gov)
    P2, N=93, Active, not recruiting, Jonsson Comprehensive Cancer Center | Trial completion date: Sep 2025 --> Sep 2033 | Trial primary completion date: Sep 2024 --> Sep 2032
    Trial completion date • Trial primary completion date
    |
    lutetium zadavotide guraxetan (PNT2002)
    4ms
    PSMA Therapy and Immunotherapy in Kidney Cancer (clinicaltrials.gov)
    P1/2, N=37, Not yet recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Initiation date: Jul 2024 --> Nov 2024
    Trial initiation date • Metastases
    |
    Keytruda (pembrolizumab) • lutetium zadavotide guraxetan (PNT2002)
    5ms
    Phase I/II 225Ac-J591 Plus 177Lu-PSMA-I&T for Progressive Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1/2, N=48, Suspended, Weill Medical College of Cornell University | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial primary completion date • Metastases
    |
    lutetium zadavotide guraxetan (PNT2002) • Ac-225 rosopatamab tetraxetan (CONV01-α)
    7ms
    177Lu-PSMA (177Lu-PNT2002) in PSMA-Positive Adenoid Cystic Carcinoma (clinicaltrials.gov)
    P2, N=10, Not yet recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Initiation date: Apr 2024 --> Jul 2024
    Trial initiation date
    |
    lutetium zadavotide guraxetan (PNT2002)
    8ms
    PSMA Therapy and Immunotherapy in Kidney Cancer (clinicaltrials.gov)
    P1/2, N=37, Not yet recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    New P1/2 trial • Metastases
    |
    Keytruda (pembrolizumab) • lutetium zadavotide guraxetan (PNT2002)
    8ms
    177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study (clinicaltrials.gov)
    P2, N=93, Active, not recruiting, Jonsson Comprehensive Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    lutetium zadavotide guraxetan (PNT2002)
    9ms
    177Lu-PSMA (177Lu-PNT2002) in PSMA-Positive Adenoid Cystic Carcinoma (clinicaltrials.gov)
    P2, N=10, Not yet recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    New P2 trial
    |
    lutetium zadavotide guraxetan (PNT2002)
    over1year
    Phase I/II 225Ac-J591 Plus 177Lu-PSMA-I&T for Progressive Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1/2; N=33 --> 48
    Enrollment change • Metastases
    |
    CELLSEARCH®
    |
    lutetium zadavotide guraxetan (PNT2002) • Ac-225 rosopatamab tetraxetan (CONV01-α)
    over1year
    Phase I/II 225Ac-J591 Plus 177Lu-PSMA-I&T for Progressive Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1/2; Recruiting --> Suspended
    Trial suspension • Metastases
    |
    CELLSEARCH®
    |
    lutetium zadavotide guraxetan (PNT2002) • Ac-225 rosopatamab tetraxetan (CONV01-α)
    over3years
    225Ac-J591 Plus 177Lu-PSMA-I&T for mCRPC (clinicaltrials.gov)
    P1/2; N=33; Recruiting; Sponsor: Weill Medical College of Cornell University; Not yet recruiting --> Recruiting
    Enrollment open
    |
    CELLSEARCH®
    |
    lutetium zadavotide guraxetan (PNT2002) • Ac-225 rosopatamab tetraxetan (CONV01-α)
    over3years
    225Ac-J591 Plus 177Lu-PSMA-I&T for mCRPC (clinicaltrials.gov)
    P1/2; N=33; Not yet recruiting; Sponsor:Weill Medical College of Cornell University
    New P1/2 trial
    |
    CELLSEARCH®
    |
    lutetium zadavotide guraxetan (PNT2002) • Ac-225 rosopatamab tetraxetan (CONV01-α)